Clinical trial • Not applicable • Gastroenterology

Amoxicillin trihydrate; Potassium clavulanate for Perianal abscess | Anal fistula

Not applicable trial of Amoxicillin trihydrate; Potassium clavulanate for Perianal abscess | Anal fistula.

Overview

Trial Therapeutic Area
Gastroenterology
Trial Disease
Perianal abscess | Anal fistula
Trial Stage
Not applicable
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
21-12-2024
First CTIS Authorization Date
14-01-2025

Trial design

Randomised, placebo (matching placebo); active treatment: amoxicillin/clavulanic acid viatris 875 mg/125 mg film-coated tablet, oral (product listed as investigational product).-controlled Not applicable trial across 1 site in Spain.

Randomised
Yes
Comparator
Placebo (matching placebo); Active treatment: Amoxicillin/clavulanic acid Viatris 875 mg/125 mg film-coated tablet, oral (product listed as investigational product).
Target Sample Size
300

Eligibility

Recruits 300 Vulnerable population not selected. Inclusion requires signed written informed consent in accordance with ICH/GCP and local legislation obtained prior to any study procedure; 'Inability to give written informed consent' is listed as an exclusion criterion..

Pregnancy Exclusion
Women with positive pregnancy test result or breast-feeding.
Vulnerable Population
Vulnerable population not selected. Inclusion requires signed written informed consent in accordance with ICH/GCP and local legislation obtained prior to any study procedure; 'Inability to give written informed consent' is listed as an exclusion criterion.

Inclusion criteria

  • {"criterion_text":"- Male or female adult patients of at least 18 years of age."}
  • {"criterion_text":"- First episode of perianal abscess."}
  • {"criterion_text":"- Oral feeding."}
  • {"criterion_text":"- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures."}
  • {"criterion_text":"- Signed written informed consent in accordance with ICH/GCP and local legislation, obtained prior to any study procedure."}

Exclusion criteria

  • {"criterion_text":"- Allergy or intolerance to amoxicillin/clavulanic acid."}
  • {"criterion_text":"- Contraindication to the performance of any of the study procedures."}
  • {"criterion_text":"- History of previous perianal surgery."}
  • {"criterion_text":"- Any clinical condition, and/or analytical alteration that, in the opinion of the investigator, is considered clinically significant enough to participate in the study. The following are considered as such: a)\tPrevious perianal fistula or fistula diagnosed during surgery. b)\tComplex abscess. c)\tMarked cellulitis after surgical drainage. d)\tHistory of inflammatory bowel disease. e)\tHistory of anal cancer. f)\tPrevious trauma or radiotherapy. g)\tDiabetes mellitus. h)\tImmunosuppressed: oncology patients, chronic corticosteroid treatment or other immunosuppressants, chronic kidney disease. i)\tProsthetic valves. j)\tMorbid obesity (BMI>40). k)\tSigns of severe sepsis"}
  • {"criterion_text":"- Women with positive pregnancy test result or breast-feeding."}
  • {"criterion_text":"- Unwillingness or inability to follow the procedures described in the protocol."}
  • {"criterion_text":"- Inability to give written informed consent."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Percentage of patients who develop perianal fistula.","definition_or_measurement_approach":""}

Secondary endpoints

  • {"endpoint_text":"- Time to onset of fistula (months).","definition_or_measurement_approach":"Time measured in months from index event to fistula onset."}
  • {"endpoint_text":"- Complexity of the fistula according to the St James´s classification.","definition_or_measurement_approach":"Assessed according to the St James classification (imaging assessment referenced in translations)."}
  • {"endpoint_text":"- Presence of new episode of perianal abscess at follow-up.","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Need for scheduled surgery for perianal fistula treatment (number of interventions, time since initial event and technique used).","definition_or_measurement_approach":"Captured as number of interventions, time since initial event and surgical technique used."}
  • {"endpoint_text":"- Quality of life questionnaire after the onset of perianal fistula (QoLAF-Q questionnaire).","definition_or_measurement_approach":"Measured using the QoLAF-Q questionnaire."}

Recruitment

Planned Sample Size
300
Recruitment Window Months
69
Consent Approach
Signed written informed consent required from each participant prior to any study procedure, in accordance with ICH/GCP and local legislation. Subjects must be adults (≥18 years). A subject information and informed consent form document is listed for publication (patient information sheet). No assent process or additional languages explicitly stated in the record.

Geography

Total Number Of Sites
1
Total Number Of Participants
300

Spain

Earliest CTIS Part Ii Submission Date
13-01-2025
Latest Decision Or Authorization Date
10-02-2026
Processing Time Days
393
Number Of Sites
1
Number Of Participants
300

Sites

Site Name
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda
Department Name
Cirugía General y del Aparato Digestivo
Contact Person Name
Verónica Polaino Moreno
Contact Person Email
fneira@idiphim.org

Sponsor

Primary sponsor

Full Name
MARIANO ARTES CASELLES
Organisation Type
Health care
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
Amoxicilina/Ácido clavulánico Viatris 875 mg/125 mg comprimidos recubiertos con película EFG
Active Substance
Amoxicillin trihydrate; Potassium clavulanate
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Authorisation Status
Authorised (marketing authorisation in Spain, marketingAuthNumber 64712)
Starting Dose
875 mg/125 mg (tablet)
Dose Levels
875 mg/125 mg
Combination Treatment
Yes

Related trials

Other published trials that may interest you.